Two types of Excedrin medications have been temporarily suspended in what the maker, GlaxoSmithKline (GSK), reportedly said was a precautionary measure.

Both Excedrin Extra Strength and Excedrin Migraine have had their production and distribution suspended because of “inconsistencies” in how the company transfers and weighs ingredients, WSYR, an ABC affiliate out of Syracuse, New York,

In a statement to CNN, GlaxoSmithKline said that it discovered the issue “through routine quality control and assurance measures,” causing the pharmaceutical company to halt production.

GlaxoSmithKline does not believe that the product poses a safety risk, and an official recall had not been made at the time of writing.

The company also told CNN that it is working to resolve the issue but does not have a definite date when the product will return to store shelves.

Shares of GlaxoSmithKline stock were up 0.38% as of 10:11 a.m. EST on Wednesday.

An illustration picture taken in Lille, France, shows pills, tablets, caplets and capsules of medicine, May 7, 2017. Getty Images